• Investment World
• eWorld
• Catalyst
• Mentor
• Life
• Canvas
• Praxis
• Urban Pulse
• Brand Quest

Stocks

• Quotes
• SE Diary
• Scoreboard
• Open-End Mutual Fund

Port Info

• Ships in Ports
  
  

Archives

• Yesterday
• Datewise
• Resources

Group Sites

• The Hindu
• Business Line
• The Sportstar
• Frontline
• The Hindu eBooks
• The Hindu Images

Our Bureau

Mumbai , March 11

Wockhardt Ltd has received the approval of regulatory authorities in the United States to market its over-the-counter (OTC) version of famotidine, an anti-ulcer drug, in the US market.

Earlier, Wockhardt had received US Food and Drug Administration (USFDA) approval to market famotidine 20-mg and 40-mg tablets, both prescription products. With the approval for famotidine 10-mg OTC medication, Wockhardt is now present in the entire product range with a combined market size of $135 million, a company communiqué said.

"Wockhardt expects to announce more approvals during the year," the note says, quoting the Wockhardt Chairman, Mr Habil Khorakiwala.

Wockhardt's US subsidiary Wockhardt USA Inc, expects to launch famotidine in the US market next month.

This is the fifth product to be launched by Wockhardt USA under the Wockhardt banner in the last few months, the others being ranitidine, enalapril, captopril and bethenecol chloride, the note said.

Article E-Mail :: Comment :: Syndication :: Printer Friendly Page

Stories in this Section
BHEL R&D initiatives start paying off — To market software for power stations with TCS

Copyright © 2005, The Hindu Business Line. Republication or redissemination of the contents of this screen are expressly prohibited without the written consent of The Hindu Business Line